Observational studyJournal of the American Heart Association2025
Utility of High-Sensitivity Cardiac Troponin-T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Survival, Quality of Life, and Functional Status Changes After Transcatheter Aortic Valve Implantation.
Observational study in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic significance of natriuretic peptides after transcatheter aortic valve replacement: A systematic review and meta-analysis.medRxiv : the preprint server for health sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiac biomarkers are minimally incorporated into current aortic valve guidelines, except for elevated BNP (B-type natriuretic peptide) in asymptomatic severe aortic stenosis. This prospective observational cohort studied how pretranscatheter aortic valve implantation (TAVI) NT-proBNP (N-terminal proBNP) and hs-cTnT (high-sensitivity cardiac troponin T) relate to mortality, quality of life, and functional outcomes after TAVI.
methodsThis is a prospective cohort study of 173 patients undergoing TAVI at a large medical center in the United States between January 1, 2020, and January 1, 2022. NT-pro-BNP and hs-cTnT, Kansas City Cardiomyopathy Questionnaire, 6-minute walk distance, and mortality were surveilled pre TAVI, and at 30 days, 1 year, and 2 years post TAVI. The patients represented a real-world cohort of patients receiving TAVI.
resultsTwo-year mortality for the entire cohort was 7.51% (13/173). In univariable analysis, higher baseline NT-pro-BNP and hs-cTnT were predictors of mortality at 2 years after TAVI. After adjusting for covariables, baseline hs-cTnT demonstrated a clinically meaningful association with mortality (
conclusionsThose with an elevated combination biomarker variable-NT-pro-BNP >357 pg/mL and hs-cTnT >14.1 ng/L-should be most rigorously surveilled and managed before and after TAVI with more frequent and comprehensive outpatient visits for medical optimization of cardiac and noncardiac disease states.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.